Trial Profile
Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Partial epilepsies; Seizures
- Focus Adverse reactions; Registrational
- Sponsors UCB; UCB Pharma SA
- 19 Aug 2023 Results published in the Epilepsia.
- 27 Apr 2023 Post-hoc analysis results assessing cognitive and behavioral effects of long-term adjunctive brivaracetam (BRV) in children with focal seizures (n=140), presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.